Apellis Receives FDA Approval for SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
Penn spinout Apellis Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for their drug SYFOVRE™ (pegcetacoplan injection).
The Philadelphia Department of Commerce recently issued a $250,000 grant to the Community College of Philadelphia (CCP) for their cell and gene therapy industry lab technician certificate program.
The Fire Awards are PHL Inno’s premiere awards program, showcasing the businesses, institutions and individuals driving the Philadelphia region’s innovation scene forward.
Once completed, the new facility, equipped with next-generation hybrid classrooms and laboratories, will support research in a variety of engineering sectors.
Onocor, a company formed through the UPstart program, has entered into an Amended and Restated License Agreement (ARLA) with Penn to expand its existing license to the ONO medical device.
Katalin Karikó and Drew Weissman received the 2022 Breakthrough Prize Award at a global ceremony hosted by television host James Corden.
Katalin Karikó Recognized in “Faces of American Innovation” Report Celebrating People Behind Life-Changing Inventions Fostered by the Bayh-Dole Act
Katalin Karikó, PhD, Adjunct Professor of Neurosurgery, was profiled in “Faces of American Innovation,” a report fostered by the Bayh-Dole Act that celebrates the people behind life-changing invention
Good Morning America features story of Emily Whitehead, the first pediatric patient to receive CAR T cell therapy
After receiving CAR T-cell treatment for leukemia in 2012, Emily is now 11 years cancer free, and is heading off to college this fall.
The cell therapy startup recently raised $17 million to advance its lead immunotherapy candidates in a second pre-Series A round of funding.
A new Philadelphia Business Journal article explains how in addition to being a hub for cell and gene therapy, the Philadelphia area is emerging as an active player in the field of gene editing.